Pharmaceutical Patent
Pioneering Solutions in Drug Development.
Invention Patents
Innovative preparation methods for APIs and intermediates.
Utility Model Patents
Innovation and creation of pharmaceutical facilities and equipment.
Autonomous Patent Authorization
Independent ownership and control of patent rights.
Development of New Product
Implementation and improvement of production processes and methods.
Product Process Improvement
Improvement of existing product processes to meet more detailed needs.
Innovation Project Research
Host and conduct provincial-level technology innovation project research.
Patents in Pharmaceutical Industry
“We are committed to protecting our innovations through pharmaceutical
patents while ensuring that they benefit a wider patient population.”
Patents are the Cornerstone of Innovation in the Pharmaceutical Industry
We are well aware that every patent is a commitment to human health and an exploration of future possibilities. We are proud to announce that we have successfully transformed 27 invention patents and 40 new patents, which have not only promoted the progress of medical technology, but also benefited patients.
What did we do?
What's News
Latest news at Tianming
Regulatory Differences Between API and Intermediate Manufacturing: A Practical Guide
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone Drug Class: What Makes This MRA Different from the Rest
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone Mechanism of Action: A Non-Steroidal MRA Built Differently
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.